2024 Interview Spotlight Series: Part I

-

This week on Simply Blood we are kicking off our Interview Spotlight Series. In Part I we are featuring the ISEH 2024 McCulloch & Till Awardee: Ravindra 'Ravi' Majeti MD, PhD. Dr. Majeti reflects on his scientific achievements, career inspirations, entrepreneurial ventures, and looks towards the future of hematologic research. Interested in hearing more about Dr. Majeti's fascinating work? Don’t miss his session at the ISEH 53rd Annual Scientific Meeting this September!





                                                                                                                                                     


Ravindra 'Ravi' Majeti MD, PhD
RZ Cao Professor of Medicine
Chief of the Division of Hematology
Member of the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
2024 McCulloch & Till Award Recipient

Interviewed by Ian Hsu of the ISEH New Investigators Committee.

Please note that the statements made by Simply Blood Authors are their own views and not necessarily the views of ISEH. ISEH disclaims any or all liability arising from any author's statements or materials.

Comments

Post a Comment

Popular posts from this blog

Transition from academia to industry: An interview with Elizabeth Paik

-
Image
We have all read many articles about the possible career choices of a scientist. The usual dilemma is between industry and academia. We have talked about this in previous blogs but the more information we get the easier it is to make a wise choice. Of course we all have opinions about the pros and cons of such a choice but what I always find best is to ask people who have experienced both. That is why I turned to an old colleague and friend, Elizabeth Paik, and asked her some questions regarding her experiences in both academia and industry. Can you describe to us your scientific career? I started my career at Harvard Medical School, as a graduate student in Dr. Len Zon's laboratory. My thesis work focused on understanding a role of CDX transcription factors during embryonic hematopoiesis. Through ChIP-seq, knockdown and overexpression studies in zebrafish, I showed CDX transcription factors control expression of hematopoietic transcription factors - SCL and LMO2. Towards the
Read more

ISEH 2024 Society Award Winners

-
Image
On behalf of the Awards Committee, ISEH would like to congratulate the recipients of the 2024 ISEH Society Awards which will be presented at the ISEH 53rd Annual Scientific Meeting . Donald Metcalf Award Winner - Emmanuelle Passegué The 2024 Donald Metcalf Award goes to Dr. Emmanuelle Passegué for her outstanding work in the fields of normal and malignant hematopoietic stem cell biology. Dr. Passegué, Alumni Professor of Genetics & Development and Director of the Columbia Stem Cell Initiative (CSCI) at Columbia University Irving Medical Center in New York city, receives the highest honor bestowed by the Society for her distinguished work as an outstanding scientist, leader, and role model.  Dr. Passegué grew up in France, and after PhD studies at the Collège de France in Paris she went on to postdoctoral research, first with Dr. Erwin Wagner at the Institute of Molecular Pathology in Vienna and with Dr. Irv. Weissman at Stanford University. In 2005, she started her own independent
Read more

Lab Spotlight: Elf Lab

-
Image
  Each month, Simply Blood spotlights a lab contributing to the fields of hematology, immunology, stem cell research, cell and gene therapies, and more. Get to know groups doing cutting edge research from around the world! This month, we are featuring the Elf Lab which is based out of the Huntsman Cancer Institute, University of Utah ( https://www.elflab.org/ ). What does your lab study? The primary focus of my lab is to understand the molecular mechanisms that govern myeloid blood cancers, with particular emphasis on MPNs. The long-term vision of my research program is to elucidate molecular dependencies specific to MPN stem cells (MPN-SCs) that can be targeted for therapeutic intervention with the ultimate goal of eradicating MPN-SCs, sparing normal HSCs, and curing the disease. When I first started my lab, we were particularly interested in how CALR mutations hijack ER stress response pathways to promote survival. Through these studies, we found that though type 1 and type 2 CALR mu
Read more